It was lovely to speak to our Expert Faculty member, Su Lwin (King’s College London, London, UK), about the development and clinical application of gene and cell therapy for individuals with epidermolysis bullosa.
- Could you give us a brief overview of epidermolysis bullosa (EB) and the unmet needs in its treatment? (0:20)
- What have been the latest advances in gene therapy for EB? (3:14)
Part 2 of our discussion can be viewed here.
Disclosures: Su Lwin had nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Share this Video
Related Videos In Dermatological Conditions
Esther van Zuuren, EADV 2021: Topical Therapies in Rosacea
It was a pleasure to speak with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) about current and emerging topical therapies in rosacea. Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021. Questions Could you give us an overview of the current […]
Esther van Zuuren, EADV 2021: Rosacea Classification
It was a pleasure to be able to catch up with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) to discuss rosacea classification and how this can impact treatment choices. Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021. Questions Could you […]
Dedee Murrell, AAD VMX 2021: BELIEVE Phase 2 Study of Rilzabrutinib in Pemphigus
It was a pleasure to be able to speak with Prof. Dedee Murrell (St George Hospital, University of New South Wales, Sydney, Australia) about the BELIEVE Phase 2 (Part A) Study (NCT02704429) which investigated the oral BTK inhibitor, rilzabrutinib, in pemphigus. Her abstract entitled ‘Treatment With Rilzabrutinib Results in Rapid and Significant Decrease in Steroid […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!